Holen Sie sich die Stockscreener-App
55.70
0.11%
-0.06
Vorhandelsmarkt:
56.98
1.28
+2.30%
Schlusskurs vom Vortag:
$55.76
Offen:
$54.95
24-Stunden-Volumen:
1.55M
Relative Volume:
0.95
Marktkapitalisierung:
$5.39B
Einnahmen:
$4.10M
Nettoeinkommen (Verlust:
$-568.53M
KGV:
-8.9668
EPS:
-6.2118
Netto-Cashflow:
$-401.18M
1W Leistung:
-2.83%
1M Leistung:
-2.41%
6M Leistung:
+19.97%
1J Leistung:
-8.76%
1-Tages-Spanne:
$53.79
$57.17
1-Wochen-Bereich:
$53.79
$60.72
52-Wochen-Spanne:
$44.12
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
55.70 | 5.39B | 4.10M | -568.53M | -401.18M | -6.2118 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
CRISPR Therapeutics' General Counsel James R. Kasinger Sells 10,400 Shares Following Option Exercise - Kalkine Media
Form 4 CRISPR Therapeutics AG For: 24 September By Investing.com - Investing.com Nigeria
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 10,400 Shares of Company Stock - MarketBeat
CRISPR Therapeutics (CRSP) counsel exercised options and sold 10,400 shares under a trading plan. - Stock Titan
CRISPR Therapeutics' Casgevy sales jump 78% in Q2, boosting long-term buy case despite AI gene editing risks - Pluang
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing (CRSP) - Seeking Alpha
CRISPR Therapeutics AG (CRSP) stock price, news, quote and history - Yahoo Finance Singapore
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
CRISPR Therapeutics AG (CRSP) Stock Price, News, Quote & History - Yahoo! Finance Canada
CRISPR Therapeutics (CRSP) Shares Dip Amid Anthropic AI Enzyme D - gurufocus.com
Gene editing stocks fall after Anthropic’s CRISPR-like discovery - Seeking Alpha
CRISPR Therapeutics AG (CRSP) Options ChainYahoo Finance - Yahoo! Finance Canada
Autologous Hematopoietic Stem Cell Gene Therapy Market - GlobeNewswire
Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race - Yahoo Finance UK
What Put the CRISPR Therapeutics (CRSP) Story on the Radar? - Kalkine Media
CRISPR Therapeutics AG (CRSP) Stock Moves 1.20%: What You Should Know - Yahoo Finance
Insider plans $626K CRISPR Therapeutics (NASDAQ: CRSP) stock sale - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Ali Behbahani Sells 13,679 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat
CRISPR Therapeutics (CRSP) director exercises options, then sells 13,679 shares around $57 - Stock Titan
Director at CRISPR Therapeutics (CRSP) gets stock in no-cash fund distribution - Stock Titan
Why CRISPR Therapeutics (CRSP) Is Back In The Spotlight - simplywall.st
New Treatment Cuts “Bad” Cholesterol in Half for a Full Year - SciTechDaily
CRISPR Therapeutics stock edges lower as investors digest latest pipeline and earnings figures - AD HOC NEWS
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026 - The Motley Fool
CRISPR Therapeutics AG (CRSP) Stock Forecasts - Yahoo Finance
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry? - TradingView
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? - The Motley Fool
CRISPR Therapeutics (NASDAQ:CRSP): What's Behind Its Stock Surge? - Kalkine Media
Director at CRISPR Therapeutics (NASDAQ: CRSP) files notice for six-figure stock sale - Stock Titan
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 11.6%What's Next? - MarketBeat
CRISPR Therapeutics Surges 11.39% as CRSP Stock Breaks Above $58RSI Oversold Picks - careplusvn.com
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Is a Good Investment: Is It? - Yahoo Finance
CRISPR Therapeutics (CRSP) Stock Looks Above Fair Value On Book Value - simplywall.st
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
CRISPR Therapeutics Eyes CASGEVY Growth, Year-End Pipeline Catalysts - Yahoo Finance
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
4 Best CRISPR Companies to Buy in 2026 and How to Invest - The Motley Fool
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
CRISPR Therapeutics (CRSP) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Trading Systems Reacting to (CRSP) Volatility - Stock Traders Daily
Why CRISPR Therapeutics Stock Rocked the Market Last Month - The Motley Fool
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - markets.businessinsider.com
Where Will CRISPR Therapeutics Stock Be in 5 Years? - The Motley Fool
Morgan Stanley's healthcare conference will feature CRISPR Therapeutics on Sept. 14 - Stock Titan
Raiffeisen Bank International AG Buys Shares of 20,000 CRISPR Therapeutics AG $CRSP - MarketBeat
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
1.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):